ERBB2 and invasive carcinoma: Consequently, if a patient is identified as being at higher risk of CEIN, and the DCIS is HER2 positive, use of HER2 targeted therapies would be of benefit in not only targeting the DCIS but also any associated undetected invasive carcinoma.